Angiotensin Converting Enzyme
Sarcoidosis - Angiotensin Converting Enzyme
Sarcoidosis is a multisystemic disorder of unknown etiology, characterized by granuloma formation.
Epidemiology
- Incidence – 10-15/100,000 in U.S.; 40/100,000 in some North European countries and among African Americans
- Age – peak incidence 20-39 years
- Sex – F>M
- Ethnicity – most prevalent in Swedish, Danish and African Americans
Risk Factors
- Family member with sarcoidosis (5-fold increased risk)
Pathophysiology
- Result of chronic immunological response associated with a genetic susceptibility and specific infections or environmental factors
- Accumulation of activated T-cells and macrophages at site of disease activity
- Lymphocytes are CD4 type
- Macrophages release cytokines that drive inflammation, granuloma formation and eventual fibrosis
Disease Stages
- Stage I – isolated thoracic lymphadenopathy
- Stage II – lymphadenopathy plus lung infiltration
- Stage III – lung infiltration
- Stage IV – overt pulmonary fibrosis
Clinical Presentation
- Asymptomatic (30-50%) diagnosed by routine chest X-ray with abnormalities of hilar adenopathy
- Nonspecific (30%) – fever, weight loss, fatigue
- Pulmonary (30%)
- Löfgren syndrome – bilateral hilar adenopathy, ankle arthritis, fever, myalgia, weight loss and erythema nodosum
- Dyspnea, wheezing
- Dermatologic – maculopapular rashes, plaques and nodules (lupus pernio), erythema nodosum and lupus pernio
- Cardiac – rhythm disorders, infiltrative cardiomyopathy and pericarditis
- Ophthalmic – anterior uveitis
- Hepatic/Splenic – granulomas, but dysfunction is rare
- Endocrine – hypercalcemia with nephrolithiasis
- Central nervous system (CNS) – neurosarcoidosis is an uncommon, but serious manifestation of sarcoidosis, affecting about 5-10% of patients
- The most common manifestations include myelopathy, cranial neuropathy and encephalopathy
- Untreated patients may develop acute neurologic emergencies, including seizures, cord compression and increased intracranial pressure
- Heerfordt’s syndrome – uveitis, parotid gland enlargement, fever and cranial neuropathy (usually 7th nerve)
Diagnosis
- Indications for testing – lymphadenopathy on chest x-ray or other appropriate clinical signs and symptoms consistent with diagnosis of sarcoidosis
- Laboratory testing
- Rule out other granulomatous diseases – consider stains and cultures for fungi and tuberculosis (TB test)
- Chemistry panel – may demonstrate hypercalcemia (~10%), hypercalcuria (~30%) or liver transaminase elevations (~20%)
- Angiotensin converting enzyme (ACE) – may have elevated level (2x normal) but this is not diagnostic for disease
- Reflects disease activity and may be useful to follow disease activity
- Cerebrospinal fluid (CSF) ACE – elevated level supports diagnosis of neurologic sarcoidosis but is not diagnostic
- Histology – presence of noncaseating granulomas
- Fiber optic bronchoscopy with bronchoalveolar lavage, transbronchial biopsy or endobronchial biopsy
- CD4/CD8 ratio higher than 3.5 is suggestive of sarcoidosis and is further supported if ACE levels are abnormal
- If criteria above are met and clinical presentation is consistent with sarcoidosis, absence of granulomas on biopsy does not negate the diagnosis of sarcoidosis
- Pulmonary function testing – full function testing with diffusing capacity of the lung for carbon monoxide (DLCO) demonstrates decreased volumes and diffusion capacity
- Imaging studies
- Pulmonary disease – high resolution CT produces better diagnostic yield than a chest X-ray; classically shows widespread micronodules with perilymphangitic distribution in middle and upper lobes (unnecessary test for most patients)
- Justified when there are atypical chest X-ray findings or normal chest X-rays but suspicion of disease
- For detection of complications of lung disease
- Central nervous system disease
Differential Diagnosis
- Chronic beryllium disease
- Fungal infection
- Hypersensitivity pneumonitis
- Malignancy – lymphoma
- Tuberculosis
- Wegener’s granulomatosis
Indications for Ordering
- Tests generally appear in the order most useful for common clinical situations
- Click on number for test-specific information in the ARUP Laboratory Test Directory
| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Angiotensin Converting Enzyme, Serum 0080001 Method: Enzymatic |
Support diagnosis of sarcoidosis or neurosarcoidosis via ACE levels in serum
Evaluate response to treatment via ACE
|
Antihypertensive medications such as ACE inhibitors, ACE receptor blockers and diuretics may interfere with test results This test is not specific for diagnosis of sarcoidosis Test is a nonspecific indicator of response to treatment In neurosarcoidosis, serum ACE concentrations are less likely to be elevated than CSF ACE concentrations. CSF ACE levels are increased in about 55% of patients with neurosarcoidosis, 5% of those with sarcoidosis (without neurologic abnormality) and 13% of those with other neurological diseases |
Further tissue biopsy and evaluation for granulomas is necessary to confirm the diagnosis
|
| Angiotensin Converting Enzyme, CSF 0098974 Method: Spectrophotometry |
Support diagnosis of sarcoidosis or neurosarcoidosis via ACE levels in CSF
Evaluate response to treatment via ACE
|
Antihypertensive medications such as ACE inhibitors, ACE receptor blockers and diuretics may interfere with test results This test is not specific for sarcoidosis Test is a nonspecific indicator of response to treatment |
|
| Lymphocyte Subsets Panel 4 - T-Cell Subsets Percents & Ratio, Bronchoalveolar Lavage 0093420 Method: Flow Cytometry |
Assist in the diagnosis of sarcoidosis when biopsy is negative
|
|
|
| Calcium, Serum or Plasma 0020027 Method: Spectrophotometry |
|
|
|
| Aspartate Aminotransferase, Serum or Plasma 0020007 Method: Enzymatic |
|
|
|
| Alanine Aminotransferase, Serum or Plasma 0020008 Method: Enzymatic |
|
|
|
| Alkaline Phosphatase, Serum or Plasma 0020005 Method: Enzymatic |
|
|
|
General References
References from the ARUP Institute for Clinical and Experimental Pathology®
Comprehensive Review: September 2008
Last Update: September 2008